Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial - Takeaways - MDSpire

Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial

  • By

  • Peter S. Hendricks

  • Sara N. Lappan

  • Richard C. Shelton

  • Adrienne C. Lahti

  • Karen L. Cropsey

  • Matthew W. Johnson

  • Melissa Bradley

  • Otto Simonsson

  • Lori L. Davis

  • Daniel H. Grossman

  • Cynthia E. Ortiz

  • May 7, 2026

  • 0 min

Share

  • 1

    Cocaine use reached record highs in 2023, with 25 million users, highlighting the urgent need for effective treatments for cocaine use disorder.

  • 2

    Psychedelics like psilocybin have shown promise in treating various substance use disorders, but no trials have specifically targeted cocaine use disorder.

  • 3

    The study employed a randomized, quadruple-blind design, comparing psilocybin with an active placebo to assess its efficacy in cocaine use disorder.

  • 4

    Participants received manualized psychotherapy alongside either psilocybin or diphenhydramine, with outcomes measured through self-reported and biochemical verification.

  • 5

    The trial aimed to determine if psilocybin could increase abstinent days and reduce cocaine use, contributing to the search for effective treatments.

Original Source(s)

Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial

  • by Peter S. Hendricks, Sara N. Lappan, Richard C. Shelton, Adrienne C. Lahti, Karen L. Cropsey, Matthew W. Johnson, Melissa Bradley, Otto Simonsson, Lori L. Davis, Daniel H. Grossman, Cynthia E. Ortiz

  • May 7, 2026

Related Content

STAT investigates the epidemic killing 178,000 Americans a year

Toward clarifying ASAM’s inpatient and residential benzodiazepine tapering recommendations

Global emergence and γ-aminobutyric acid type A (GABAA) receptor activity of the new designer benzodiazepine ethylbromazolam